Immutep Receives New US Patent for Cancer Treatment Method; Shares Down 4%
MT Newswires Live
Jul 14
Immutep (ASX:IMM) obtained a fourth patent from the US Patent and Trademark Office related to its cancer treatments, according to a Tuesday filing with the Australian bourse.
The new patent, which covers methods to treat cancer by administering eftilagimod alfa in combination with PD-1 pathway inhibitors, has an expiry date of Jan. 20, 2036, per the filing.
The company is evaluating eftilagimod alfa in a variety of solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma, soft tissue sarcoma, and breast cancer.
Immutep shares fell nearly 4% in recent Tuesday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.